The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation
Open accessAbstract
Use of warfarin, clopidogrel, or aspirin associates with mortality among patients with ESRD, but the risk-benefit ratio may depend on underlying comorbidities. Here, we investigated the association between these medications and new stroke, mortality, and hospitalization in a retrospective cohort analysis of 1671 incident hemodialysis patients with preexisting atrial fibrillation. We followed patient outcomes from the time of initiation of dialysis for an average of 1.6 yr. Compared with nonuse, warfarin use associated with a significantly increased risk for new stroke (hazard ratio 1.93; 95% confidence interval 1.29 to 2.90); clopidogrel or aspirin use did not associate with increased risk for new stroke. Analysis using international normalized ratio (INR) suggested a dose-response relationship between the degree of anticoagulation and new stroke in patients on warfarin (P = 0.02 for trend). Warfarin users who received no INR monitoring in the first 90 d of dialysis had the highest risk for stroke compared with nonusers (hazard ratio 2.79; 95% confidence interval 1.65 to 4.70). Warfarin use did not associate with statistically significant increases in all-cause mortality or hospitalization. In conclusion, warfarin use among patients with both ESRD and atrial fibrillation associates with an increased risk for stroke. The risk is greatest in warfarin users who do not receive in-facility INR monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Warfarin use was associated either with a neutral or increased risk of stroke in database analyses of patients on dialysis, [419][420][421] including a population-based analysis in Canada (adjusted HR for stroke 1.14; 95% CI 0.78-1.67,adjusted HR for bleeding 1.44; 95% CI 1.13-1.85).422”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [420]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
EAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,877
Petersen, P., GODTFREDSEN, J., Boysen, G., Andersen, E. D., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,814
The role of the propensity score in estimating dose-response functions
Imbens, G. W. (2000) · Biometrika · doi:10.1093/biomet/87.3.706 · Cited by 1,779
Cited by
Sorted by citations
Items 301–400 of 427
Ballegaard, E. L. F., Lindhard, K., Lindhardt, M. K., Peters, C. D., Nielsen, F. T., Tietze, I. N., Borg, R., Boesby, L., Bertelsen, M., Brøsen, J. M. B., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-081961 · Cited by 4
Considerations for Systemic Anticoagulation in ESRD
Dager, W. E., Tsu, L. V., & Pon, T. K. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12376 · Cited by 4
“Unexpected critical INR values should be rechecked if possible or further assessment should be completed prior to making changes or reversing (if no acute bleeding) therapy, especially in patients who are at high risk for thrombosis (60).”
BackgroundCardiac Radiosurgery for the Treatment of Atrial Fibrillation
Bhatt, N. S., Fogarty, T. J., & Maguire, P. (2016) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2016.65015 · Cited by 4
Tanaka, A., Inaguma, D., Shinjo, H., & Takeda, A. (2019) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2018.1530085 · Cited by 4
“Patients with AF receiving maintenance dialysis have shown poor prognosis [5,6], and previously, we showed that patients with AF at the time of dialysis introduction had high CVD incidence and mortality rates [7].”
BackgroundManagement of Atrial Fibrillation in Patients With Kidney Disease.
Lau, Y. C., & Lip, G. Y. H. (2014) · PubMed Central · doi:10.4022/jafib.989 · Cited by 4
The Debate on Warfarin Use in Dialysis Patients With Atrial Fibrillation: More Fuel for the Fire
Bansal, N. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.04.017 · Cited by 4
On Warfarin Use in Kidney Disease: A Therapeutic Window of Opportunity?
Nolin, T. D. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.09.007 · Cited by 4
Cardiovascular and Stroke Risk in Japanese Hemodialysis Patients With Atrial Fibrillation
Hasegawa, J., Bieber, B. A., Larkina, M., Robinson, B. M., Wakai, S., Akizawa, T., Saitō, A., Fukuhara, S., & Akiba, T. (2016) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12460 · Cited by 4
“risk of stroke in AF patients with non-ESRD or ESRD, some studies have warned that warfarin use did not reduce stroke events (7,20), but increased”
BackgroundMłodawska, E., Łopatowska, P., Małyszko, J., Banach, M., Sobkowicz, B., Covic, A. C., & Tomaszuk−Kazberuk, A. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-1877-y · Cited by 4
Kimura, A., Tanaka, M., Moniwa, N., Osanami, A., Abe, K., Miyamori, D., Gocho, Y., Shibata, S., Terasawa, M., Okazaki, Y., et al. (2020) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01991-9 · Cited by 3
Velasco, E. B., de la Flor, J. C., de la Manzanara, V. L., y, L. N.-F., Narváez-Mejía, C., Vega, L. L. C., Villa, D. E., Zamora, R., Tapia, M., Sastre, M. Á., et al. (2024) · Medicina · doi:10.3390/medicina60020231 · Cited by 3
Wyld, M. L. R., Clayton, P. A., Morton, R. L., & Chadban, S. J. (2013) · Nephrology · doi:10.1111/nep.12170 · Cited by 3
“94)..(21,26) Our base case assumption for the model is that aspirin use does not impact haemorrhagic stroke risk.”
BackgroundMethodResultInfluentialPraehauser, C., Grandjean, R., Steiger, J., & Mayr, M. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2013.13730 · Cited by 3
Cerebrovascular disease in end-stage kidney disease
Tsuruya, K., & Fujisaki, K. (2016) · Renal Replacement Therapy · doi:10.1186/s41100-016-0044-0 · Cited by 3
“[14] investigated the association between this medication and new stroke, mortal-”
BackgroundA hemodialysis cohort study of protocol-based anticoagulation management
Lamontagne, S., Basein, T., Chang, B., & Mallela, L. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2381-7 · Cited by 3
“If the ontarget anticoagulation rate in our study is reflective of the typical TTR in the hemodialysis patient population at large it could, in part, explain the large degree of uncertainty as to the overall benefit of warfarin anticoagulation (especially for stroke prevention in atrial fibrillation) in the dialysis p…”
BackgroundShould Oral Anticoagulation Be Used in ESKD Patients on Hemodialysis with Atrial Fibrillation?: PRO
Devabhaktuni, S. R., & Mounsey, J. P. (2021) · Kidney360 · doi:10.34067/kid.0000022021 · Cited by 3
“Uremia is associated with a vasculopathy and this may in itself elevate stroke risk independent of any mitigation by anticoagulation(16).”
BackgroundAnticoagulation in special patient populations with atrial fibrillation
Ueberham, L., & Hindricks, G. (2021) · Herz · doi:10.1007/s00059-021-05042-1 · Cited by 4
Warfarin therapy for atrial fibrillation in haemodialysis patients: mind the (evidence) gap
Szummer, K. E., & Carrero, J. J. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu412 · Cited by 3
“These associations may not be entirely universal, but perhaps confined to special high-risk subpopulations, such as individuals above 75 years of age [7], or receiving high warfarin dosages [5] presumably denoting poor international normalized ratio (INR) control.”
BackgroundWarfarin in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease
Garrick, R. E. (2012) · Yearbook of Medicine · doi:10.1016/j.ymed.2012.08.029 · Cited by 3
Neurologic Complications of Chronic Kidney Disease
Murray, A. M., Seliger, S. L., & Stendahl, J. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00021-4 · Cited by 3
Verdades y controversias de la anticoagulación en fibrilación auricular no valvular
Gómez-Rosero, J. A., & Sierra-Vargas, E. C. (2019) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2019.07.006 · Cited by 3
Süfling, L., Greinert, D., & Girndt, M. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab008 · Cited by 3
Chronic kidney disease as a risk factor for acute stroke
Rzhevskaya, O. N., Moiseeva, A., Esaulenko, A. N., Pinchuk, A., & Alidzhanova, K. (2021) · Transplantologiya. The Russian Journal of Transplantation · doi:10.23873/2074-0506-2021-13-4-382-397 · Cited by 2
Soriano, R. M. S., Molina, M. D. A., Fernández, C. I. C., Juliá‐Sanchis, R., López-Menchero, R., Fernández, C. D. P., Jornet, G. G., & Villota, J. N. (2018) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2018.06.007 · Cited by 3
End-Stage Renal Disease, Nonvalvular Atrial Fibrillation, and the Warfarin Dilemma
McBane, R. D. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.04.023 · Cited by 3
Chang, T., Chan, Y., Chao, T., Lin, C., Lin, Y., Chang, S., Lo, L., Hu, Y., Chung, F., & Chen, S. (2025) · Journal of Arrhythmia · doi:10.1002/joa3.70094 · Cited by 2
Optimal Thromboembolism Prevention for Patients With Atrial Fibrillation on Long‐Term Dialysis
Hashimoto, K., Fujisaki, T., Aikawa, T., Iwagami, M., Miyamoto, Y., Slipczuk, L. N., Biase, L. D., Briasoulis, Α., Yasuhara, J., Takagi, H., et al. (2025) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.15208 · Cited by 2
Kumar, A., Kumar, C., Kumar, A., Kumari, S., Aneela, Rai, R., Kumar, A., Kumar, K., Gyaneshwari, Aslam, H., et al. (2025) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i3.105485 · Cited by 2
Implications of Kidney Disease in the Cardiac Patient
Rear, R., Meier, P., & Bell, R. M. (2014) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2014.03.001 · Cited by 2
Christensen, M. A., Fosbøl, E. L., Bonde, A. N., Olesen, J. B., Gislason, G., Torp-Pedersen, C. T., & Gundlund, A. (2019) · EP Europace · doi:10.1093/europace/euz340 · Cited by 2
Yang, Z., Wang, J., Yuan, Y., Cheng, T., Ren, F., Wang, S., & Zhang, Z. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1021959 · Cited by 2
“Eligible cohort studies and RCTs that reported efficacy outcomes [composite of stroke and systemic embolism (SSE), ischemic stroke (ICS), and systemic embolization] or safety outcomes [major bleeding, intracranial hemorrhage (ICH), and gastrointestinal bleeding (GIB)] of rivaroxaban in NVAF patients with ESKD were enr…”
BackgroundInfluentialEffect of conventional hemodialysis on the apixaban plasma concentration
Poel, T., de Rouw, N., Péquériaux, N. C. V., van de Kerkhof, D., den Tweel, A. M. A. V. W.-V., van Marum, R. J., & Kerckhoffs, A. P. M. (2023) · Hemodialysis International · doi:10.1111/hdi.13127 · Cited by 2
“…to Chan et al. and Elliott et al., ESRD patients have an increased bleeding risk when concomitantly treated with coumarin derivatives and other types of anticoagulation like LMWHs. 12,13 Our data do not confirm the feared risk of overcoagulation due to adding LMWH to the hemodialysis system.”
BackgroundLauterbach, M., Uhrich, E., Eggebrecht, L., Göbel, S., Panova‐Noeva, M., Nagler, M., ten Cate, V., Bickel, C., Espinola–Klein, C., Münzel, T. F., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030645 · Cited by 2
“Interestingly, dialysis patients with atrial fibrillation were paradoxically found to have a higher risk of stroke with the use of warfarin [10,11].”
BackgroundAdministration tri-hebdomadaire de la warfarine en hémodialyse chronique. Résultats chez 12 patients
Poux, J., Dardim, K., Nguyen, Q. T., Arnaud, G., Rouby, M., & Manescu, M. (2013) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2013.05.008 · Cited by 2
Vardi, M., Yeh, R. W., Herzog, C. A., Winkelmayer, W. C., Setoguchi, S., & Charytan, D. M. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05130513 · Cited by 2
Neurologic Aspects of Kidney Disease
Tamura, M. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10058-2 · Cited by 2
Schlieper, G., Schwenger, V., Remppis, A. B., Keller, T., Dechend, R., Maßberg, S., Baldus, S. E., Weinreich, T., Hetzel, G. R., Floege, J., et al. (2017) · RWTH Publications (RWTH Aachen) · Cited by 2
Uso de anticoagulantes orales en situaciones clínicas complejas con fibrilación auricular
Gullón, A., Fuentes, D. S., de Sá, E. L., Martí‐Almor, J., Barón‐Esquivias, G., Jiménez-López, J. I., Muruaga, M. D. M. C., & Fernández, C. S. (2018) · Medicina Clínica · doi:10.1016/s0025-7753(18)30666-3 · Cited by 2
Bonde, A. N., Kamper, A., & Olesen, J. B. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.081 · Cited by 2
Anticoagulation for Atrial Fibrillation in Advanced Chronic Kidney Disease
Genovesi, S., & Ronco, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_25 · Cited by 1
González, S., & Calvo, J. A. H. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2022.01.013 · Cited by 1
Oral anticoagulant therapy in patients with atrial fibrillation and end-stage chronic kidney disease
Simić, J., & Mihajlovic, M. (2024) · Galenika Medical Journal · doi:10.5937/galmed2412058s · Cited by 1
Yang, Y., Lee, S. H., Hwang, W., Jung, J. H., & Park, J. (2026) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.052 · Cited by 1
Alshogran, O. Y. (2014) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Anticoagulation for Atrial Fibrillation in End-stage Kidney Disease
Lee, G., & Johnson, D. W. (2015) · Journal of Controversies in Biomedical Research · doi:10.15586/jcbmr.2015.9 · Cited by 1
“(41) of six observational cohort studies (8, 16-18, 38, 39) provides the highest level of evidence so far until a RCT can be implemented.”
Background3. Cerebrovascular Disease in Chronic Kidney Disease
Tsuruya, K. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.825 · Cited by 1
Non-vitamin K antagonist oral anticoagulants for heart diseases
Борисовна, К. Т., Popova, L. V., & Николаевич, Б. И. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh2017899120-127 · Cited by 1
“Данные канадских исследователей свидетельствуют о нейтральном и даже отрицательном влиянии варфарина на риск развития инсульта у таких лиц [34, 35].”
Contemporary approach to stroke prevention in atrial fibrillation: Risks, benefits, and new options
Stock, J., & Malm, B. J. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.03.004 · Cited by 1
Stroke and Atrial Fibrillation in Chronic Kidney Disease and Dialysis
Collister, D., & Walsh, M. W. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55429-9.00014-5 · Cited by 2
Warfarin Dosing and Outcomes in Chronic Kidney Disease: A Closer Look at Warfarin Disposition
Alshogran, O. Y. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190701095807 · Cited by 1
Prevalence and Characteristics of Atrial Fibrillation in Turkish Patients Undergoing Hemodialysis
Hasbal, N. B., Koç, Y., Şakacı, T., Sevinç, M., Uçar, Z. A., Şahutoğlu, T., Akgöl, C., Ahbap, E., Ünsal, A., & Baştürk, T. (2020) · Turkish Journal of Nephrology · doi:10.5152/turkjnephrol.2020.4130 · Cited by 1
Neurologic Complications of Chronic Kidney Disease
Seliger, S. L., & Waddy, S. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00029-2 · Cited by 1
Peritoneal dialysis in the setting of acute brain injury: an underappreciated modality
Wang, E. J., Kim, S., Wang, A. H., Jiang, W., & Shah, A. D. (2023) · Hospital Practice · doi:10.1080/21548331.2023.2241340 · Cited by 1
“In HD patients with preexisting atrial fibrillation, the use of warfarin was associated with increased risk for new stroke but clopidogrel and aspirin were not [40].”
BackgroundKardiovaskuläre Therapie bei chronischer Nierenerkrankung
Brandenburg, V. M., Saritas, T., Schirmer, S. H., Rogacev, K. S., & Heine, G. H. (2023) · Herz · doi:10.1007/s00059-023-05205-2 · Cited by 1
Otsuka, E., Kitamura, M., Sawase, K., Nakamura, M., Inoue, H., Yamaguchi, K., Funakoshi, S., Takazono, T., Mukae, H., & Nishino, T. (2023) · Internal Medicine · doi:10.2169/internalmedicine.2180-23 · Cited by 1
Does pharmacotherapy improve cardiovascular outcomes in hemodialysis patients?
Mittal, M., Aggarwal, K. B., Littrell, R. L., Agrawal, H., & Alpert, M. (2015) · Hemodialysis International · doi:10.1111/hdi.12352 · Cited by 1
Fibrillation auriculaire et anticoagulation chez le patient hémodialysé : une décision difficile
Delanaye, P., Bouquegneau, A., Dubois, B., Sprynger, M. G., Mariat, C., Krzesinski, J.-M., & Lancellotti, P. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2016.09.002 · Cited by 1
Impact of the Number of Anti-Thrombosis Agents in Hemodialysis Patients: BOREAS-HD2 Study
Tanaka, M., Moniwa, N., Ohnishi, H., Yamashita, T., Koyama, M., Gocho, Y., Nishizawa, K., Kimura, Y., Sugawara, H., Murakami, S., et al. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000480487 · Cited by 1
Nutritional And Biochemical Evaluation Of Vitamin K Enriched Dietary Sources
Muhammad, Y. (2013) · HEC National Digital Library · Cited by 1
Stroke Risk in Maintenance Hemodialysis
Herrington, W. G., & Lewis, D. A. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.02.338 · Cited by 1
Weigert, A. L. L., & Herzog, C. A. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Chung, T.-W. (2026) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.406 · Cited by 1
Kunzendorf, U. (2013) · Der Nephrologe · doi:10.1007/s11560-013-0790-8
Israel, C. W., Ridjab, D. A., Tschishow, W. N., & Buddecke, J. (2013) · Herzschrittmachertherapie + Elektrophysiologie · doi:10.1007/s00399-013-0266-6
Martin, A., Thilly, N., Ayav, C., Clerc‐Urmès, I., Held, P., Frimat, L., & Peters, N. O. (2015) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2015.07.020
Thomson, P. C. (2010) · Enlighten: Theses (The University of Glasgow)
Hypertension, chronic kidney disease, atrial fibrillation and the newer anticoagulants
Rayner, B. L. (2012) · South African Family Practice · doi:10.1080/20786204.2012.10874263
Warfarin: safe in dialysis patients with atrial fibrillation?
Quinn, R. R., & Scott‐Douglas, N. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.212
“have considered this important and clinically relevant question and found that hemodialysis patients being treated with warfarin for atrial fibrillation had a higher unadjusted rate of stroke than untreated patients or those treated with aspirin or clopidogrel”
ResultHörl, W. H. (2009) · Wiener klinische Wochenschrift · doi:10.1007/s00508-009-1272-x
“Warfarin use did not associate with statistically significant increase in all-cause mortality or hospitalization [ 15 ].”
BackgroundQuestions pratiques dans le traitement de la fibrillation atriale
Éderhy, S., Lang, S., Haddour, N., Boyer-Châtenet, L., Soulat-Dufour, L., Adavane-Scheublé, S., Fleury, G., Vynckt, C. V. D., Charbonnier, M., Asri, C. E., et al. (2013) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(13)70889-9
Quinn, K. M., Ingram, A. J., & Hart, R. G. (2014) · Springer eBooks · doi:10.1007/978-3-319-09162-4_4
Warfarin in patients on haemodialysis with atrial fibrillation—friend or foe?
Qamar, A., & Bhatt, D. L. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.103
Warfarin therapy on hemodilysis patient with atrial fibrillation ―It can be harmful
IWASAKI, M., & Hase, H. (2013) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.24.286
A review from clinical viewpoint
Yasaka, M. (2011) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.22.156
Successful endovascular therapy in a hemodialysis patient with acute ischemic stroke
Ishizuka, A., Nakamura, S., Kishida, M., Ohta, Y., Hayashi, S.-I., Yoshihara, F., Hayakawa, M., Yamagami, H., Miyashita, K., Nagatsuka, K., et al. (2016) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.49.253
Werns, S. W. (2010) · Yearbook of Critical Care Medicine · doi:10.1016/s0734-3299(10)79394-1
Akao, M., Abe, M., Esato, M., Chun, Y., Wada, H., & Hasegawa, K. (2013) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.24.290
A case of superior mesenteric artery occlusion occuring one month after dialysis initiation
Yasuda, K., Sasaki, K., Hatanaka, M., Isaka, Y., Rakugi, H., & Hayashi, T. (2011) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.44.323
Inhaled Glucocorticoids and Adult Height
Chaisson, R. E., & Nuermberger, E. L. (2012)
Shen, J. I., Montez‐Rath, M. E., Lenihan, C. R., Turakhia, M. P., Chang, T. I., & Winkelmayer, W. C. (2015)
Dialysing the Elderly Patient with Congestive Heart Failure: What Is Important to Know?
Davenport, A. (2015) · Springer eBooks · doi:10.1007/978-1-4939-3320-4_12
Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
Chan, K. E., Edelman, E. R., Wenger, J., Thadhani, R., & Maddux, F. W. (2014) · DSpace@MIT (Massachusetts Institute of Technology)
of Kidney Disease in the Cardiac Patient
Rear, R., Meier, P., & Bell, R. M. (2014)
Binder, H., Kurz, T., Teschner, S., Kreutz, C., Geyer, M., Donauer, J., Kraemer-Guth, A., Timmer, J., Schumacher, M. C., & Walz, G. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0210-9
“Moreover, anticoagulation and platelet inhibitors negatively affect survival of hemodialysis patients; in a large meta-analysis, patients exposed to warfarin, clopidogrel, and/or aspirin had significantly increased mortality rates [36, 37].”
BackgroundThrombozytenhemmer und Antikoagulanzien bei Nierenerkrankungen
Lutz, J., & Jurk, K. (2016) · Der Nephrologe · doi:10.1007/s11560-016-0108-8
“Auf der anderen Seite zeigten Studien aber auch einen therapeutischen Vorteil einer Behandlung mit Warfarin bei Dialysepatienten mit Vorhofflimmern.”
BackgroundInfluentialAkamatsu, H., Higuchi, N., Tateishi, Y., Tsujino, A., Horie, N., Izumo, T., Sasaki, H., & Kitahara, T. (2016) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.42.168
Lau, Y. C. (2017) · University of Birmingham Institutional Research Archive (University of Birmingham)
In Reply to ‘International Normalized Ratio Control in Patients With Atrial Fibrillation and CKD’
Jun, M., & Hemmelgarn, B. R. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.02.368
Lullo, L. D., Floccari, F., Rivera, R. F., Bàrbera, V., Bellasi, A., Cozzolino, M. G., Selvi, A., Santoboni, F., Pascalis, A. D., & Ronco, C. (2017) · Giornale di Techniche Nefrologiche e Dialitiche · doi:10.5301/gtnd.2017.17030
Sudden Cardiac Death and Dysrhythmia in Hemodialysis Patients
Hase, H. (2012) · Japanese Journal of Electrocardiology · doi:10.5105/jse.32.321
Besondere Bedeutung der Antikoagulation bei Dialysepatienten
Müller‐Ehmsen, J., & Rafflenbeul, E. (2017) · Der Internist · doi:10.1007/s00108-017-0274-4
Anticoagulants for Atrial Fibrillation
Senoo, K., & Lip, G. Y. H. (2017) · Cardiovascular medicine · doi:10.1007/978-3-319-58000-5_9
Martin, A., Thilly, N., Ayav, C., Clerc‐Urmès, I., Held, P., Frimat, L., & Peters, N. O. (2015) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2015.08.005
Hristova, M., van Beek, C., Schurgers, L. J., Lanske, B., & Danziger, J. (2010)
Carta ao Editor. Antagonistas da Vitamina K em Hemodiálise: Será o Benefício Superior ao Risco?
Godinho, I., & Weigert, A. L. L. (2018) · Acta Médica Portuguesa · doi:10.20344/amp.9800
Tsuruya, K. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.926
Anticoagulation for Atrial Fibrillation in Patients with End- Stage Kidney Disease
Tran, Q. B., Jebeili, B., Sud, K., & Bose, B. (2018) · InTech eBooks · doi:10.5772/intechopen.78022
“, it was found that CKD patients requiring dialysis with AF, warfarin use, in comparison with no-warfarin use, did not reduce the risk for stroke however it was associated with a 44% higher risk for having a bleeding event, whereas warfarin use in nondialysis patients with AF was associated with a 13% lower risk for s…”
BackgroundKidney Disease and Medications
Winkelmayer, W. C. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0987-2.00015-7
4. Efficasy and Safety of DOAC Versus Warfarin in Chronic Kidney Disease
Tsuruya, K. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.856
Lullo, L. D., Floccari, F., Rivera, R. F., Bàrbera, V., Bellasi, A., Cozzolino, M. G., Selvi, A., Santoboni, F., Pascalis, A. D., & Ronco, C. (2017) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2017.653
Metadata
- Authors
- Chan, K. E., Lazarus, J. M., Thadhani, R., & Hakim, R. M.
- Affiliations
- Fresenius Medical Care (United States) (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Chan, Kevin E.
- Lazarus, J. Michael
- Hakim, Raymond M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2009-10
- Volume
- 20
- Issue
- 10
- Pages
- 2223-2233
- ISSN
- 1046-6673 (ISSN-L)
- PMC
- PMC2754104
- OpenAlex
- W2137138584
- Cited by
- 431
- References
- 86
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 12 · 2023: 17 · 2022: 15 · 2021: 20 · 2020: 23 · 2019: 21 · 2018: 38 · 2017: 40 · 2016: 40 · 2015: 43 · 2014: 34 · 2013: 35 · 2012: 29
- FWCI
- 16.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- warfarin, stroke risk, hemodialysis, atrial fibrillation, end-stage renal disease, clopidogrel, aspirin, INR monitoring, anticoagulation, mortality, hospitalization
- MeSH terms
- Aged, Anticoagulants, Atrial Fibrillation, Female, Renal Dialysis, Hospitalization, Humans, Kidney Failure, Chronic, Male, Regression Analysis, Retrospective Studies, Risk, Warfarin, Cohort Studies, International Normalized Ratio, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
